4Kawaharada M, Urasawaa K. Immunological functions and clinical course of elderly patients with cerebrovascular diseases. Nippon Ronen Igakkai zasshi,1992,29 (9):652-660.
5Tarkouski E,Naver H,Wallin BG,et al. Lateralization of lymphocyte responses in paitents with stroke:effect of sympathetic stroke or effect of sympathetic dysfuntion? Stroke, 1995,26:57-62.
6Dietrlch G,Kazatchkine MD. Normal immunoglobulin G(IgG) for therapeutic use contains antiidotypic specificities against an immunodominant,disease-associated,crossreactive idiotype of human anti-thromboglobulin autoantibodies. J Clin Invest, 1990,85:620-625.
7Dalakas MC. Intravenous immune globuljun therapy for neurologic diseased. Ann Intern Med, 1997,136:721-730.
8Martinkiewicz J,Szymanowskaz J,Mazurek A,et al. Immunoregulatory mechanisms of action of intravenous gammaglobulin in Kawasaki syndrome. Przegl Lek, 1998,55:613-659.
9Harukawa H, Yuasa T. Progress of the therapy for virus-related neurological disorders. Nippon Rinsho, 1997,55:959-966.
3Cowl CT,Weinstock JV,Al-Jurf A,et al.Complications and cost associated with parenteral nutrition delivered to hospitalized patients through either subclavian or peripherally-inserted central catheters[J].Clin Nutr,2000,19(4):237-243.
